In this issue of Blood, Boulaftali and colleagues have made the important and novel observation that deficiency of the serine protease inhibitor (serpin), PN-1, in platelets results in a prothrombotic state, supporting the role of platelet PN-1 in thrombosis. 1 S pecifically, Boulaftali et al have initially confirmed previously published studies by Gronke et al indicating that protease nexin-1 (PN-1) is expressed by platelets. 2 In studies on human platelets from healthy donors and from patients with the gray platelet syndrome (␣-granular deficiency), the authors demonstrate that PN-1 is stored in platelet ␣-granules, from which it is secreted into plasma and bound to the platelet membrane. There, it inhibits thrombin and urokinasetype plasminogen activator (uPA) and reduces thrombin generation by tissue factor (TF). Platelets from PN-1-deficient mice demonstrate increased sensitivity to thrombin in Pselectin expression and platelet aggregation. Thrombus formation, induced ex vivo by collagen under blood flow conditions and in vivo by ferric chloride-induced injury, was significantly increased in PN-1-deficient mice, demonstrating the antithrombotic properties of platelet PN-1. These studies demonstrate that platelet PN-1 has important antithrombotic properties that have heretofore gone unrecognized.
It has been amply demonstrated that, in addition to playing a part in primary hemostasis by adhering to sites of vascular injury and aggregating to form the initial platelet plug, activated platelets have an essential role in blood coagulation by exposing receptors and assembling active enzymatic complexes for virtually all the coagulation proteins of the contact and consolidation pathways of the clotting cascade 3 (see figure) . What is less well appreciated is the regulatory role played by activated platelets in the secretion of coagulation inhibitors that limit the generation and activity of thrombin, localize active coagulation complexes to the platelet surface, and prevent uncontrolled intravascular thrombotic processes (see figure) . Thus, for example, in addition to the serpin PN-1, another potent inhibitor stored in and secreted from platelet ␣-granules is the Kunitz-type inhibitor (kunin), protease nexin-2 (PN-2). PN-2 is otherwise known as the Alzheimer ␤-amyloid Schematic diagram representing the procoagulant and anticoagulant properties of activated platelets. The crescentic forms represent the activated platelet membrane, except in the case of the form labeled "TF•PL," which represents tissue factor expressed on a phospholipid membrane surface. The roman numerals represent coagulation proteins including zymogens or substrates (in circles), enzymes (in circles with segmental excisions), and cofactors (in ellipses). The curved arrows represent conversions from zymogens (eg, prothrombin, shown as II) to active enzymes (eg, thrombin, shown as IIa), whereas the left-pointing arrows represent the inhibition of these active enzymes (eg, factor Xa, shown as Xa) to their inactivated forms (eg, inactivated factor Xa, shown as Xi). Shown in boxes are the Kunitz-type inhibitors, protease nexin-2 (PN-2) and tissue factor pathway inhibitor (TFPI), and the serpin, protease nexin-1 (PN-1). The initiation of the coagulation mechanism occurs as the consequence of the assembly of the FVIIa/FX/TF/PL complex and is regulated by TFPI, whereas the consolidation phase of coagulation, regulated by PN-2 and PN-1, is activated by the resulting generation of low concentrations of thrombin sufficient to activate platelets, FXI, FVIII, and FV to produce thrombin in sufficient quantities to form a fibrin clot. For personal use only. on April 8, 2017. by guest www.bloodjournal.org From protein precursor, which contains a Kunitztype protease inhibitor domain. 4, 5 Whereas PN-1 is a potent and specific inhibitor of thrombin, PN-2 operates by an entirely different mechanism, characteristic of the kunins, to serve as a potent (K i ϳ 500pM) and highly specific inhibitor of the unique, homodimeric coagulation proteinase, factor XIa (FXIa). Both PN-2 and PN-1 are present in plasma at concentrations far too low to inhibit their cognate proteinases, but are secreted from platelet ␣-granules to achieve high concentrations (ϳ 30nM in the case of PN-2) in the surrounding plasma. This is sufficient to inhibit enzymes at the initiation (FXIa) and termination (thrombin) of the consolidation pathway of coagulation, thereby preventing the propagation of intravascular coagulation beyond the nidus of the platelet hemostatic thrombus.
Another important inhibitory mechanism relevant to the observations of Boulaftali et al 1 involves another Kunitz-type inhibitor, tissue factor pathway inhibitor (TFPI), which regulates the initiation of blood coagulation at sites of vascular injury. 6 In contrast to PN-1 and PN-2, however, TFPI is present in human plasma at high enough concentrations to inhibit FVIIa and FXa and the generation of thrombin. Once sufficient quantities of FXa have been formed to produce thrombin at the low concentrations required to activate platelets, FXI, FVIII, and FV, the consolidation pathway of blood clotting produces thrombin in sufficient quantities to convert fibrinogen to fibrin and form a hemostatic thrombus. 6 Moreover, platelets contain approximately 10% of the TFPI in blood and can release sufficient TFPI to increase the concentration roughly 3-fold to further inhibit the TF pathway. 6 These new findings, 1 interpreted in the context of our current knowledge of procoagulant and anticoagulant mechanisms mediated by activated platelets, emphasize the importance of the yin and yang of platelets in blood coagulation. Defects in the procoagulant contributions of platelets to the assembly of coagulation complexes (yang) results in hemorrhagic complications, whereas defects in the anticoagulant mechanisms (yin) produce serious thrombotic consequences that account for the vast majority of premature deaths in Western societies.
Conflict-of-interest disclosure: The author declares no competing financial interests. ■ 
Platelet RNA chips dip into thrombocytosis ----------------------------------------------------------------------------------------------------------------Srikanth Nagalla and Paul F. Bray THOMAS JEFFERSON UNIVERSITY
In this issue of Blood, Gnatenko and colleagues have conducted studies to determine whether platelet RNA profiling can predict causes of thrombocytosis. 1 The authors show that expression levels of only 4 platelet transcripts are able to predict JAK2 V617F-negative ET in more than 85% of samples.
T hrombocytosis is a relatively common hematologic abnormality and is associated with iron deficiency, malignancy, and chronic inflammatory processes. Chronic myeloproliferative disorders (polycythemia vera [PV], essential thrombocythemia [ET] and primary myelofibrosis [PMF] ) are important albeit less common causes. Hematologists are often consulted to exclude myeloproliferative disease (MPD) as a cause of high platelet counts. Most often, the clinical picture does not present difficulties distinguishing MPD from reactive thrombocytosis (RT). Among the MPDs with thrombocytosis, ET is typically considered after PV and PMF have been excluded. The somatic mutation V617F in the Janus kinase 2 gene (JAK2) distinguishes MPD from RT, but only half of patients with ET express the JAK2 V617F mutation. 2 Thus, biomarkers specific for ET patients who are JAK2 V617F-negative would have diagnostic value and possibly provide mechanistic insights.
The authors' earlier work has shown that platelet gene expression can distinguish ET from healthy persons. 3 In the current study, 126 subjects were recruited: 48 healthy controls, 40 ET patients, and 38 RT patients. The investigators have fabricated a novel "platelet gene chip," which contains probes for 432 mRNAs. Most of these transcripts are reportedly expressed exclusively or predominantly in platelets; a small subset is expressed predominantly in leukocytes, permitting assessment of leukocyte contamination. Using an initial cohort of subjects as a "training set," sophisticated statistical analyses identified 11 transcripts, the expression of which effectively distinguished the 3 study groups. One hundred percent of the RT subjects and 87.5% of the ET patients were classified correctly using the 11 transcripts measured by the microarray analysis. Importantly, these findings were validated by qRT-PCR in 10 randomly selected subjects from each of the ET and RT cohorts. To validate further this set of biomarkers, the 11 genes were used to predict the phenotype in 31 additional subjects with thrombocytosis. Using platelet RNA, qRT-PCR was able to correctly classify 87% of these subjects. The authors provide evidence that expression levels of only 4 transcripts (HIST1H1A, SRP72, C20orf103, and CRYM) were able to predict JAK2 V617F-negative ET patients in more than 85% of samples.
RNA expression profiling has been used in a variety of diseases for the purpose of identifying novel genes involved in the pathophysiology, as well as for diagnostic and prognostic purposes. Only a few studies have considered
